Were Analysts Bullish Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) This Week?

April 16, 2018 - By Clifton Ray

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) LogoInvestors sentiment increased to 3.89 in 2017 Q4. Its up 2.53, from 1.36 in 2017Q3. It increased, as 5 investors sold Idera Pharmaceuticals, Inc. shares while 13 reduced holdings. 35 funds opened positions while 35 raised stakes. 142.24 million shares or 202.82% more from 46.97 million shares in 2017Q3 were reported.
Leavell Investment has invested 0.02% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). California Employees Retirement stated it has 0% in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Citigroup accumulated 0% or 14,630 shares. State Board Of Administration Of Florida Retirement Sys has 0% invested in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) for 19,240 shares. State Common Retirement Fund accumulated 96,300 shares. Bnp Paribas Arbitrage invested in 29,251 shares. 48,919 were reported by Premier Asset Limited Liability Corporation. Deutsche Bancorporation Ag holds 0% or 310,011 shares. Cambridge Inv Rech Advsr invested in 0% or 18,000 shares. Balyasny Asset Mngmt Limited Co holds 0% or 59,416 shares. 22,587 are held by Metropolitan Life Insur. Morgan Stanley reported 356,570 shares stake. Broadfin Limited Liability Com has invested 0.7% of its portfolio in Idera Pharmaceuticals, Inc. (NASDAQ:IDRA). Two Sigma Ltd Liability Company reported 16,220 shares. Parallax Volatility Advisers Limited Partnership reported 21,588 shares or 0% of all its holdings.

Since October 26, 2017, it had 1 insider purchase, and 2 sales for $7.00 million activity. The insider BAKER BROS. ADVISORS LP bought $12.00 million.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Ratings Coverage

Among 2 analysts covering Idera Pharmaceuticals (NASDAQ:IDRA), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Idera Pharmaceuticals had 4 analyst reports since November 9, 2017 according to SRatingsIntel. H.C. Wainwright maintained it with “Buy” rating and $4.0 target in Friday, March 9 report. The firm has “Buy” rating by H.C. Wainwright given on Thursday, November 16. On Thursday, November 9 the stock rating was maintained by Piper Jaffray with “Buy”. Below is a list of Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) latest ratings and price target changes.

09/03/2018 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
16/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: Piper Jaffray Rating: Buy New Target: $4.0 Maintain
09/11/2017 Broker: H.C. Wainwright Rating: Buy New Target: $4 Initiates Coverage On

The stock decreased 0.18% or $0.0034 during the last trading session, reaching $1.8666. About 153,879 shares traded. Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) has declined 21.96% since April 16, 2017 and is downtrending. It has underperformed by 33.51% the S&P500.

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company has market cap of $403.20 million. It uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and third-generation antisense technology. It currently has negative earnings. The companyÂ’s drug candidates include IMO-2125, an agonist that is in Phase I/II clinical trials in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma and refractory solid tumors; IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.